



Press release from Emotra AB (publ)
Göteborg, November 26, 2021

Emotra announces the exercise price for subscription warrants in the TO 2 series

On November 25, 2021, Emotra AB (“Emotra” or “the Company”) established the exercise price for subscription warrants in the TO 2 series (“the Subscription warrants”). The exercise price has been set to SEK 0.26 per new share purchased through the exercise of Subscription warrants.

If all subscription warrants are exercised, this new share issue will provide the Company with approximately MSEK 4.1 before issue expenses. These expenses are expected to amount to approximately MSEK 0.2.

Terms and conditions for Subscription warrants

Terms and conditions: one (1) subscription warrant allows the shareholder to purchase one (1) new share.

Exercise price: 0.26 SEK per share; not subject to broker’s fees.

Exercise period: November 29 through December 13, 2021.

For further information about Emotra, please contact:

Daniel Poté, President, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company’s method, EDOR®, is a proprietary and objective psychophysiological test for identifying hyporeactive patients.